Jonas Rodny News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jonas rodny. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jonas Rodny Today - Breaking & Trending Today
The Worldcom Public Relations Group: Worldcom Public Relations Group Welcomes New Partners in Sweden and Chile finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Betsson : Chairman Patrick Svensk is resigning from the Board marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands 27 January 2021 Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands Immunicum AB (publ; IMMU.ST) announced today that its in-house research and process development activities will move into a new facility at the Leiden Bio Science Park, the Netherlands. The Company has signed a long-term lease with developer Kadans Science Partner for approximately 1,100 square meters of laboratory and office space in the Plus Ultra Leiden, a new building currently under development. Furthermore, Immunicum has the option to rent an additional 1,100 square meters to further support its future growth. The new location, that is expected to be fully commissioned in 2022, will serve as Immunicum s core research and development hub. ....
Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Combination Clinical Trial 17 December 2020 Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Combination Clinical Trial Topline results on safety and dosing from Phase Ib portion of trial expected during Q3 2021 Phase II portion of trial can initiate following selection of dose regimen from Phase Ib trial Immunicum AB (publ; IMMU.ST) announced today the completion of patient recruitment for the Phase Ib portion of the ongoing ILIAD (ILIxadencel in combination with checkpoint inhibitors in ADvanced cancer patients) trial. The primary objective of the Phase Ib study is to evaluate the safety and tolerability as well as define the dose regimen for Immunicum s lead cell-based candidate, ilixadencel, in combination with the checkpoint inhibitor (CPI), Keytruda (pembrolizumab), in a total of 21 patients. ....